Anixa Biosciences Presents Positive Phase 1 Data for Ovarian Cancer CAR-T Therapy at ISCT 2026
Event summary
- Anixa Biosciences will present Phase 1 trial data for lira-cel, its CAR-T therapy targeting recurrent ovarian cancer, at the ISCT 2026 Annual Meeting in Dublin.
- The presentation, led by Cheryl Cox of Moffitt Cancer Center, will detail the trial design and current status of lira-cel, which targets the follicle-stimulating hormone receptor (FSHR).
- Lira-cel is uniquely differentiated by its use of chimeric endocrine receptor-T cell (CER-T) technology, leveraging the natural ligand FSH instead of antibody fragments.
- The ongoing Phase 1 trial (NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies.
The big picture
Anixa Biosciences' presentation at the ISCT 2026 Annual Meeting underscores the growing importance of targeted immunotherapies in oncology. The company's focus on CER-T technology represents a strategic pivot from traditional CAR-T approaches, potentially offering a more precise and effective treatment for recurrent ovarian cancer. With partnerships with leading cancer research institutions, Anixa is positioning itself at the forefront of next-generation cell therapies, aiming to address high-unmet needs in cancer treatment.
What we're watching
- Clinical Efficacy
- How the positive survival data from the Phase 1 trial will influence the progression to later-stage trials and potential regulatory approval.
- Competitive Positioning
- Whether Anixa's CER-T technology can differentiate lira-cel in the crowded CAR-T therapy market, particularly for ovarian cancer.
- Partnership Strategy
- The pace at which Anixa can leverage its collaborations with Moffitt Cancer Center and Cleveland Clinic to advance its vaccine portfolio alongside lira-cel.
Related topics